-
1
-
-
0028798304
-
Goals of antihypertensive therapy
-
McVeigh GE, Flack J, Grimm R. Goals of antihypertensive therapy. Drugs 49(2): 161-175, 1995.
-
(1995)
Drugs
, vol.49
, Issue.2
, pp. 161-175
-
-
McVeigh, G.E.1
Flack, J.2
Grimm, R.3
-
2
-
-
34249658468
-
A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma
-
DOI 10.1016/j.jchromb.2007.02.014, PII S1570023207001134
-
Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, Gu J. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B 852: 436-442, 2007. (Pubitemid 46830149)
-
(2007)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.852
, Issue.1-2
, pp. 436-442
-
-
Li, H.1
Wang, Y.2
Jiang, Y.3
Tang, Y.4
Wang, J.5
Zhao, L.6
Gu, J.7
-
3
-
-
0030750293
-
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
-
Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 54(2): 299-311, 1997. (Pubitemid 27361837)
-
(1997)
Drugs
, vol.54
, Issue.2
, pp. 299-311
-
-
Markham, A.1
Goa, K.L.2
-
4
-
-
28444479429
-
Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine
-
DOI 10.1016/j.jchromb.2005.09.015, PII S1570023205006537
-
Nie J, Zhang M, Fan Y, Wen Y, Xiang B, Feng YQ. Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine. J Chromatogr B 828: 62-69, 2005. (Pubitemid 41735300)
-
(2005)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.828
, Issue.1-2
, pp. 62-69
-
-
Nie, J.1
Zhang, M.2
Fan, Y.3
Wen, Y.4
Xiang, B.5
Feng, Y.-Q.6
-
5
-
-
0030979588
-
Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
-
DOI 10.1007/s002280050259
-
Flesch G, Lloyd P, Müller PH. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52: 115-120, 1997. (Pubitemid 27239595)
-
(1997)
European Journal of Clinical Pharmacology
, vol.52
, Issue.2
, pp. 115-120
-
-
Flesch, G.1
Muller, P.2
Lloyd, P.3
-
6
-
-
0029549912
-
Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist
-
Criscione L, Bradley W, Buhlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, Gasparo MD. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13(3): 230-250, 1995. (Pubitemid 26110791)
-
(1995)
Cardiovascular Drug Reviews
, vol.13
, Issue.3
, pp. 230-250
-
-
Criscione, L.1
Bradley, W.A.2
Buhlmayer, P.3
Whitebread, S.4
Glazer, R.5
Lloyd, P.6
Mueller, P.7
De Gasparo, M.8
-
7
-
-
0029969837
-
The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
-
DOI 10.1016/S0149-2918(96)80040-3
-
Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Firzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 18(5): 797-810, 1996. (Pubitemid 26397279)
-
(1996)
Clinical Therapeutics
, vol.18
, Issue.5
, pp. 797-810
-
-
Oparil, S.1
Dyke, S.2
Harris, F.3
Kief, J.4
James, D.5
Hester, A.6
Fitzsimmons, S.7
-
8
-
-
0027172062
-
1-receptor subtype
-
Criscione L, Gasparo M, Buhlmayer P, Whitebread S, Ramjoune HP, Wood J. Pharmacological profile of valsartan; a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110(2): 761-771, 1993. (Pubitemid 23279290)
-
(1993)
British Journal of Pharmacology
, vol.110
, Issue.2
, pp. 761-771
-
-
Criscione, L.1
De Gasparo, M.2
Buhlmayer, P.3
Whitebread, S.4
Ramjoue, H.-P.R.5
Wood, J.6
-
9
-
-
8244241166
-
Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects
-
Flesch G, Muller Ph, Degen P, Lloyd P, Dieterle W. Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects. Eur J Drug Metab Pharmacokinet 18: 256-260, 1993.
-
(1993)
Eur J Drug Metab Pharmacokinet
, vol.18
, pp. 256-260
-
-
Flesch, G.1
Muller, Ph.2
Degen, P.3
Lloyd, P.4
Dieterle, W.5
-
10
-
-
0031969656
-
An interaction study with cimetidine and the new angiotensin II antagonist valsartan
-
DOI 10.1007/s002280050406
-
Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 53: 451-458, 1998. (Pubitemid 28154746)
-
(1998)
European Journal of Clinical Pharmacology
, vol.53
, Issue.6
, pp. 451-458
-
-
Schmidt, E.K.1
Antonin, K.-H.2
Flesch, G.3
Racine-Poon, A.4
-
11
-
-
55049094798
-
Electrochemical behavior of valsartan and its determination in capsules
-
Yan J, Chen L, Chen S. Electrochemical behavior of valsartan and its determination in capsules. Colloids Surf B Biointerfaces 67: 205-209, 2008.
-
(2008)
Colloids Surf B Biointerfaces
, vol.67
, pp. 205-209
-
-
Yan, J.1
Chen, L.2
Chen, S.3
-
13
-
-
45449100112
-
A simple and efficient synthesis of the valsartan
-
Zhang CX, Zheng GJ, Bi FQ, Li YL. A simple and efficient synthesis of the valsartan. Chin Chem Lett 19: 759-761, 2008.
-
(2008)
Chin Chem Lett
, vol.19
, pp. 759-761
-
-
Zhang, C.X.1
Zheng, G.J.2
Bi, F.Q.3
Li, Y.L.4
-
14
-
-
0035468033
-
Physicochemical profiling (solubility, permeability and charge state)
-
Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1(4): 277-351, 2001.
-
(2001)
Curr Top Med Chem
, vol.1
, Issue.4
, pp. 277-351
-
-
Avdeef, A.1
-
15
-
-
0035292910
-
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract
-
Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv Drug Del Rev 46: 75-87, 2001.
-
(2001)
Adv Drug del Rev
, vol.46
, pp. 75-87
-
-
Horter, D.1
Dressman, J.B.2
-
16
-
-
0034950807
-
Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets
-
DOI 10.1016/S0939-6411(01)00147-3, PII S0939641101001473
-
Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 52: 75-82, 2001. (Pubitemid 32594790)
-
(2001)
European Journal of Pharmaceutics and Biopharmaceutics
, vol.52
, Issue.1
, pp. 75-82
-
-
Takka, S.1
Rajbhandari, S.2
Sakr, A.3
-
17
-
-
17644380257
-
Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
-
DOI 10.1007/s11095-004-9004-4
-
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1): 11-23, 2005. (Pubitemid 40558141)
-
(2005)
Pharmaceutical Research
, vol.22
, Issue.1
, pp. 11-23
-
-
Wu, C.-Y.1
Benet, L.Z.2
-
18
-
-
0028948839
-
A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product and in vivo bioavailability
-
Amidon GL, Lennernas H, Shah VP, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product and in vivo bioavailability. Pharm Res 12(3): 413-420, 1995.
-
(1995)
Pharm Res
, vol.12
, Issue.3
, pp. 413-420
-
-
Amidon, G.L.1
Lennernas, H.2
Shah, V.P.3
Crison, J.4
-
19
-
-
0037026364
-
Comparison of UV- And second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation
-
DOI 10.1016/S0731-7085(02)00360-6, PII S0731708502003606
-
Tatar S, Saglik S. Comparison of UV- and second derivative- spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J Pharm Biomed Anal 30(2): 371-375, 2002. (Pubitemid 35013504)
-
(2002)
Journal of Pharmaceutical and Biomedical Analysis
, vol.30
, Issue.2
, pp. 371-375
-
-
Tatar, S.1
Salk, S.2
-
20
-
-
0037040623
-
Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection
-
DOI 10.1016/S0021-9673(01)01496-0, PII S0021967301014960
-
Gonzalez L, Lopez JA, Alonso RM, Jimenez RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A 949: 49-60, 2002. (Pubitemid 34183413)
-
(2002)
Journal of Chromatography A
, vol.949
, Issue.1-2
, pp. 49-60
-
-
Gonzalez, L.1
Lopez, J.A.2
Alonso, R.M.3
Jimenez, R.M.4
-
21
-
-
0031022244
-
14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
-
DOI 10.1080/004982597240767
-
Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Buhlmayer P, Gasparo MD. Pharmacokinetics, disposition and biotransformation of [ 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27(1): 59-71, 1997. (Pubitemid 27068372)
-
(1997)
Xenobiotica
, vol.27
, Issue.1
, pp. 59-71
-
-
Waldmeier, F.1
Flesch, G.2
Muller, P.3
Winkler, T.4
Kriemler, H.-P.5
Buhlmayer, P.6
De Gasparo, M.7
-
22
-
-
0030575831
-
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester
-
DOI 10.1016/S0378-4347(96)00242-3, PII S0378434796002423
-
Francotte E, Davatz A, Richert P. Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester. J Chromatogr B 686(1): 77-83, 1996. (Pubitemid 26382460)
-
(1996)
Journal of Chromatography B: Biomedical Applications
, vol.686
, Issue.1
, pp. 77-83
-
-
Francotte, E.1
Davatz, A.2
Richert, P.3
-
23
-
-
0033168125
-
Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma
-
DOI 10.1021/ac981294y
-
Steinborner S, Henion J. Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal Chem 71: 2340-2345, 1999. (Pubitemid 29307595)
-
(1999)
Analytical Chemistry
, vol.71
, Issue.13
, pp. 2340-2345
-
-
Steinborner, S.1
Henion, J.2
-
24
-
-
0034525745
-
A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine
-
Gonzalez L, Alonso RM, Jimenez RM. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine. Chromatographia 52(11): 735-740, 2000. (Pubitemid 32042686)
-
(2000)
Chromatographia
, vol.52
, Issue.11-12
, pp. 735-740
-
-
Gonzalez, L.1
Alonso, R.M.2
Jimenez, R.M.3
-
25
-
-
0036160364
-
High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method
-
DOI 10.1016/S0378-4347(01)00507-2, PII S0378434701005072
-
Daneshtalab N, Lewanczuk RZ, Jamali F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B 766: 345-349, 2002. (Pubitemid 34142367)
-
(2002)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.766
, Issue.2
, pp. 345-349
-
-
Daneshtalab, N.1
Lewanczuk, R.Z.2
Jamali, F.3
-
26
-
-
33745588527
-
A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets
-
Perez M, Cardenas W, Ramirez G, Perez M, Restrepo P. A comparative cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets. Colomb Med 37(2): 114-120, 2006. (Pubitemid 43984086)
-
(2006)
Colombia Medica
, vol.37
, Issue.2
, pp. 114-120
-
-
Perez, M.1
Cardenas, W.2
Ramirez, G.3
Perez, M.4
Restrepo, P.5
-
27
-
-
32244447228
-
Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography
-
DOI 10.1016/j.jchromb.2005.12.035, PII S157002320600002X
-
Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B 832(1): 169-172, 2006. (Pubitemid 43213025)
-
(2006)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.832
, Issue.1
, pp. 169-172
-
-
Macek, J.1
Klima, J.2
Ptacek, P.3
-
28
-
-
33746242339
-
Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography
-
Kocyigit-Kaymakcioglu B, Unsalan S, Rollas S. Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography. Pharmazie 61(7): 586-589, 2006. (Pubitemid 44098024)
-
(2006)
Pharmazie
, vol.61
, Issue.7
, pp. 586-589
-
-
Kocyigit-Kaymakcoglu, B.1
Unsalan, S.2
Rollas, S.3
-
29
-
-
33750455117
-
Optimization via experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples
-
DOI 10.1002/jssc.200600093
-
Iriarte G, Ferreiros N, Ibarrondo I, Alonso RM, Maguregi MI, Gonzalez L, Jimenez RM. Optimization via experimental design of an SPE- HPLC- UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples. J Sep Sci 29(15): 2265-2283, 2006. (Pubitemid 44649640)
-
(2006)
Journal of Separation Science
, vol.29
, Issue.15
, pp. 2265-2283
-
-
Iriarte, G.1
Ferreiros, N.2
Ibarrondo, I.3
Alonso, R.M.4
Maguregi, M.I.5
Gonzalez, L.6
Jimenez, R.M.7
-
30
-
-
34848830402
-
Biovalidation of an SPE-HPLC-UV-fluorescence method for the determination of Valsartan and its metabolite valeryl-4-hydroxy-valsartan in human plasma
-
DOI 10.1002/jssc.200700033
-
Iriarte G, Ferreiros N, Ibarrondo I, Alonso RM, Maguregui I, Jimenez RM. Biovalidation of an SPEHPLC- UV-fluorescence method for the determination of valsartan and its metabolite valeryl-4-hydroxyvalsartan in human plasma. J Sep Sci 30(14): 2231-2240, 2007. (Pubitemid 47497024)
-
(2007)
Journal of Separation Science
, vol.30
, Issue.14
, pp. 2231-2240
-
-
Iriarte, G.1
Ferreiros, N.2
Ibarrondo, I.3
Alonso, R.M.4
Maguregui, M.I.5
Jimenez, R.M.6
-
31
-
-
52449117747
-
Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: Application for pharmacokinetic studies
-
Zarghi A, Shafaati A, Fooutan SM, Movahed H. Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: application for pharmacokinetic studies. Sci Pharm 76: 439-450, 2008.
-
(2008)
Sci Pharm
, vol.76
, pp. 439-450
-
-
Zarghi, A.1
Shafaati, A.2
Fooutan, S.M.3
Movahed, H.4
-
32
-
-
77953428438
-
Validated HPLC method development: The simultaneous analysis of amlodipine and valsartan in samples for liver perfusion studies
-
Çelebier M, Sinan Kaynak MS, Altinöz S, Şahin S. Validated HPLC method development: the simultaneous analysis of amlodipine and valsartan in samples for liver perfusion studies. Hacettepe Univ J Fac Pharm 28(1): 15-30, 2008.
-
(2008)
Hacettepe Univ J Fac Pharm
, vol.28
, Issue.1
, pp. 15-30
-
-
Çelebier, M.1
Sinan Kaynak, M.S.2
Altinöz, S.3
Şahin, S.4
-
33
-
-
41049106938
-
Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method
-
DOI 10.1002/jssc.200700442
-
Ferreiros N, Iriarte G, Alonso RM, Jimenez RM, Ortiz E. Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method. J Sep Sci 31(4): 667-676, 2008. (Pubitemid 351419571)
-
(2008)
Journal of Separation Science
, vol.31
, Issue.4
, pp. 667-676
-
-
Ferreiros, N.1
Iriarte, G.2
Alonso, R.M.3
Jimenez, R.M.4
Ortiz, E.5
-
34
-
-
51849105198
-
Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection
-
Piao ZZ, Lee ES, Tran HTT, Beom-Jin Lee BJ. Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. Arch Pharm Res 31(8): 1055-1059, 2008.
-
(2008)
Arch Pharm Res
, vol.31
, Issue.8
, pp. 1055-1059
-
-
Piao, Z.Z.1
Lee, E.S.2
Tran, H.T.T.3
Beom-Jin Lee, B.J.4
-
35
-
-
52149120600
-
Simultaneous determination of valsartan and hydrochlorothiazide in tablets by RP-HPLC
-
Tian DF, Tian XL, Tian T, Wang ZY, Mo FK. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by RP-HPLC. Ind J Pharm Sci 70: 372-374, 2008.
-
(2008)
Ind J Pharm Sci
, vol.70
, pp. 372-374
-
-
Tian, D.F.1
Tian, X.L.2
Tian, T.3
Wang, Z.Y.4
Mo, F.K.5
-
36
-
-
0031932550
-
1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats
-
DOI 10.1016/S0731-7085(97)00128-3, PII S0731708597001283
-
Soldner A, Spahn-Langguth H, Mutschler E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal 16: 863-873, 1998. (Pubitemid 28097414)
-
(1998)
Journal of Pharmaceutical and Biomedical Analysis
, vol.16
, Issue.5
, pp. 863-873
-
-
Soldner, A.1
Spahn-Langguth, H.2
Mutschler, E.3
-
37
-
-
0344431303
-
Determination of SK and F 108566 (Teveten(R)) in human plasma by reversed-phase high-performance liquid chromatography
-
DOI 10.1016/S0378-4347(97)00598-7, PII S0378434797005987
-
Lundberg DE, Person CR, Knox S, Cyronak MJ. Determination of SK&F 108566 (Teveten) in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 707: 328-333, 1998. (Pubitemid 28198072)
-
(1998)
Journal of Chromatography B: Biomedical Applications
, vol.707
, Issue.1-2
, pp. 328-333
-
-
Lundberg Jr., D.E.1
Renee, P.C.2
Knox, S.3
Cyronak, M.J.4
-
38
-
-
0029781981
-
Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization
-
DOI 10.1002/(SICI)1096-9888(199608)31:8<873::AID-JMS368>3.0.CO;2-J
-
Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom 31: 873-878, 1996. (Pubitemid 26258965)
-
(1996)
Journal of Mass Spectrometry
, vol.31
, Issue.8
, pp. 873-878
-
-
Kondo, T.1
Yoshida, K.2
Yoshimura, Y.3
Motohashi, M.4
Tanayama, S.5
-
39
-
-
0035816463
-
Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine
-
DOI 10.1016/S0039-9140(01)00379-4, PII S0039914001003794
-
Cagigal E, Gonzalez L, Alonso RM, Jimenez RM. Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine. Talanta 54: 1121-1133, 2001. (Pubitemid 32607144)
-
(2001)
Talanta
, vol.54
, Issue.6
, pp. 1121-1133
-
-
Cagigal, E.1
Gonzalez, L.2
Alonso, R.M.3
Jimenez, R.M.4
-
40
-
-
33947382605
-
Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry
-
DOI 10.1016/j.jpba.2006.12.030, PII S0731708506008351
-
Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, Nagae Y, Masuda N. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatographytandem mass spectrometry. J Pharm Biomed Anal 43: 1769-1774, 2007. (Pubitemid 46453072)
-
(2007)
Journal of Pharmaceutical and Biomedical Analysis
, vol.43
, Issue.5
, pp. 1769-1774
-
-
Koseki, N.1
Kawashita, H.2
Hara, H.3
Niina, M.4
Tanaka, M.5
Kawai, R.6
Nagae, Y.7
Masuda, N.8
-
41
-
-
34848835442
-
Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study
-
DOI 10.1016/j.jchromb.2007.08.016, PII S1570023207005867
-
Selvan PS, Gowda V, Mandal U, Solomon WDS, Pal TK. Simultaneous determination of fixed dose combination of nevobiolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. J Chromatogr B 858: 143-150, 2007. (Pubitemid 47513603)
-
(2007)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.858
, Issue.1-2
, pp. 143-150
-
-
Selvan, P.S.1
Gowda, K.V.2
Mandal, U.3
Solomon, W.D.S.4
Pal, T.K.5
-
42
-
-
62249174362
-
Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry
-
Levi M, Grégoire Wuerzner G, Ezan E, Pruvost A. Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry. J Chromatogr B 877(10): 919-926, 2009.
-
(2009)
J Chromatogr B
, vol.877
, Issue.10
, pp. 919-926
-
-
Levi, M.1
Grégoire Wuerzner, G.2
Ezan, E.3
Pruvost, A.4
-
43
-
-
59049089752
-
Recent development in derivative ultraviolet/visible absorption spectrophotometry
-
Rojas FS, Ojeda CB. Recent development in derivative ultraviolet/visible absorption spectrophotometry. Anal Chim Acta 635: 22-44, 2009.
-
(2009)
Anal Chim Acta
, vol.635
, pp. 22-44
-
-
Rojas, F.S.1
Ojeda, C.B.2
-
44
-
-
0033863645
-
Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography
-
Carlucci G, Carlo V, Mazzeo P. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography. Anal Lett 33(12): 2491-2500, 2000.
-
(2000)
Anal Lett
, vol.33
, Issue.12
, pp. 2491-2500
-
-
Carlucci, G.1
Carlo, V.2
Mazzeo, P.3
-
45
-
-
0035001665
-
Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC
-
DOI 10.1016/S0731-7085(01)00394-6, PII S0731708501003946
-
Satana E, Altinay S, Goger NG, Ozkan SA, Senturk Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 25(5): 1009-1013, 2001. (Pubitemid 32488968)
-
(2001)
Journal of Pharmaceutical and Biomedical Analysis
, vol.25
, Issue.5-6
, pp. 1009-1013
-
-
Satana, E.1
Altinay, S.2
Goger, N.G.3
Ozkan, S.A.4
Senturk, Z.5
-
46
-
-
0037467027
-
Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis
-
DOI 10.1016/S0731-7085(02)00643-X, PII S073170850200643X
-
Hillaert S, Van den Bossche W. Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J Pharm Biomed Anal 31(2): 329-339, 2003. (Pubitemid 36254815)
-
(2003)
Journal of Pharmaceutical and Biomedical Analysis
, vol.31
, Issue.2
, pp. 329-339
-
-
Hillaert, S.1
Van Den, B.W.2
-
47
-
-
77954612609
-
Stability indicating RP-HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation
-
Chitlange SS, Bagri K, Sakarkar DM. Stability indicating RP-HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation. Asian J Research Chem 1(1): 15-18, 2008.
-
(2008)
Asian J Research Chem
, vol.1
, Issue.1
, pp. 15-18
-
-
Chitlange, S.S.1
Bagri, K.2
Sakarkar, D.M.3
-
48
-
-
34447109035
-
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
-
DOI 10.1016/j.clinthera.2007.03.018, PII S0149291807001002
-
Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Two multicenter, 8- week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29(4): 563-580, 2007. (Pubitemid 47028551)
-
(2007)
Clinical Therapeutics
, vol.29
, Issue.4
, pp. 563-580
-
-
Philipp, T.1
Smith, T.R.2
Glazer, R.3
Wernsing, M.4
Yen, J.5
Jin, J.6
Schneider, H.7
Pospiech, R.8
-
49
-
-
0037667643
-
Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation
-
Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24(3): 261-271, 2003. (Pubitemid 36733542)
-
(2003)
Endocrine Reviews
, vol.24
, Issue.3
, pp. 261-271
-
-
Carey, R.M.1
Siragy, H.M.2
-
50
-
-
63749129568
-
2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults
-
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 53(15): 1343-1382, 2009.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.15
, pp. 1343-1382
-
-
Hunt, S.A.1
Abraham, W.T.2
Chin, M.H.3
Feldman, A.M.4
Francis, G.S.5
-
51
-
-
61849183176
-
Heart failure
-
Krum H, Abraham WT. Heart failure. Lancet 373: 941-955, 2009.
-
(2009)
Lancet
, vol.373
, pp. 941-955
-
-
Krum, H.1
Abraham, W.T.2
-
52
-
-
62949182264
-
Efficacy and safety of two treatment combinations of hypertension in very elderly patients
-
Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 48: 401-405, 2009.
-
(2009)
Arch Gerontol Geriatr
, vol.48
, pp. 401-405
-
-
Fogari, R.1
Zoppi, A.2
Mugellini, A.3
Corradi, L.4
Lazzari, P.5
Preti, P.6
Derosa, G.7
-
53
-
-
34247130486
-
The future of antihypertensive treatment
-
DOI 10.1097/01.pap.0000249915.12185.58, PII 0004539120070300000003
-
Israili ZH, Hernandez RH, Valasco M. The future of antihypertensive treatment. Am J Ther 14: 121-134, 2007. (Pubitemid 46597649)
-
(2007)
American Journal of Therapeutics
, vol.14
, Issue.2
, pp. 121-134
-
-
Israili, Z.H.1
Hernandez-Hernandez, R.2
Valasco, M.3
-
54
-
-
0029024577
-
Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991
-
Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26(1): 60-69, 1995.
-
(1995)
Hypertension
, vol.26
, Issue.1
, pp. 60-69
-
-
Burt, V.L.1
Cutler, J.A.2
Higgins, M.3
Horan, M.J.4
Labarthe, D.5
Whelton, P.6
Brown, C.7
Roccella, E.J.8
-
56
-
-
0029133769
-
Use of angiotensin II antagonists in human heart failure: Function of the subtype 1 receptor
-
Zagrosek VR, Neuss M, Holzmeister J, Fleck E. Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. J Hypertens 13(1): 63-71, 1995.
-
(1995)
J Hypertens
, vol.13
, Issue.1
, pp. 63-71
-
-
Zagrosek, V.R.1
Neuss, M.2
Holzmeister, J.3
Fleck, E.4
-
57
-
-
0029943358
-
Current drug treatment and treatment patterns with antihypertensive drugs
-
Freis ED, Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 52(1): 1-16, 1996. (Pubitemid 26193489)
-
(1996)
Drugs
, vol.52
, Issue.1
, pp. 1-16
-
-
Freis, E.D.1
Papademetriou, V.2
-
58
-
-
0030716908
-
Do we need angiotensin II antagonists to treat hypertensive patients?
-
Menard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 11(2): 1-7, 1997.
-
(1997)
J Hum Hypertens
, vol.11
, Issue.2
, pp. 1-7
-
-
Menard, J.1
Chatellier, G.2
Azizi, M.3
-
59
-
-
0034912836
-
Angiotensin II subtype 1 receptor blockers and renal function
-
Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 161: 1492-1499, 2001. (Pubitemid 32679561)
-
(2001)
Archives of Internal Medicine
, vol.161
, Issue.12
, pp. 1492-1499
-
-
Toto, R.1
-
60
-
-
0036828691
-
Lessons learned from the Valsartan- Heart Failure Trial (Val-HeFT): Angiotensin receptor blockers in heart failure
-
DOI 10.1016/S0002-9149(02)02667-X, PII S000291490202667X
-
Cohn J. Lessons learned from the valsartan-heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol 90: 992-993, 2002. (Pubitemid 35232624)
-
(2002)
American Journal of Cardiology
, vol.90
, Issue.9
, pp. 992-993
-
-
Cohn, J.N.1
-
61
-
-
34548542222
-
Rationale for Combining Blockers of the Renin-Angiotensin System
-
DOI 10.1016/j.semnephrol.2007.07.002, PII S0270929507000873, Hypertension and the kidney: New Avenues for an Improved Management of Hypertension in Renal Diseases
-
Azizi M, Wuerzner G. Rationale for combining blockers of the renin-angiotensin system. Semin Nephrol 27(5): 544-554, 2007. (Pubitemid 47381469)
-
(2007)
Seminars in Nephrology
, vol.27
, Issue.5
, pp. 544-554
-
-
Azizi, M.1
Wuerzner, G.2
-
62
-
-
0033069767
-
Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH)
-
Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH). J Hypertens 17: 151-183, 1999.
-
(1999)
J Hypertens
, vol.17
, pp. 151-183
-
-
-
63
-
-
45149087687
-
Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trial
-
DOI 10.1016/j.clinthera.2008.01.012, PII S014929180800060X
-
Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 30(1): 108-120, 2008. (Pubitemid 351834726)
-
(2008)
Clinical Therapeutics
, vol.30
, Issue.1
, pp. 108-120
-
-
Hermida, R.C.1
Ayala, D.E.2
Khder, Y.3
Calvo, C.4
-
64
-
-
55949116516
-
Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: A multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study
-
Rump LC, Baranova E, Okopien B, Weisskopf M, Kandra A, Ferber P. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study. Clin Ther 30(10): 1782-1793, 2008.
-
(2008)
Clin Ther
, vol.30
, Issue.10
, pp. 1782-1793
-
-
Rump, L.C.1
Baranova, E.2
Okopien, B.3
Weisskopf, M.4
Kandra, A.5
Ferber, P.6
-
65
-
-
0032802509
-
Clinical advantage of valsartan
-
McInnes GT. Clinical advantage of valsartan. Cardiology 91 (Suppl 1): 14-18, 1999. (Pubitemid 29371542)
-
(1999)
Cardiology
, vol.91
, Issue.SUPPL. 1
, pp. 14-18
-
-
McInnes, G.T.1
-
66
-
-
0028117856
-
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
-
Müller P, Cohen T, Gasparo M, Sioufi A, Racinepoon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy normotensive subjects. Eur J Clin Pharmacol 47(3): 231-245, 1994. (Pubitemid 24330665)
-
(1994)
European Journal of Clinical Pharmacology
, vol.47
, Issue.3
, pp. 231-245
-
-
Muller, P.1
Cohen, T.2
De Gasparo, M.3
Sioufi, A.4
Racine-Poon, A.5
Howald, H.6
-
67
-
-
0030814394
-
Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours
-
DOI 10.1016/S0149-2918(97)80129-4
-
Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang YT, Gatliq M. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 19(3): 447-458, 1997. (Pubitemid 27292598)
-
(1997)
Clinical Therapeutics
, vol.19
, Issue.3
, pp. 447-458
-
-
Neutel, J.1
Weber, M.2
Pool, J.3
Smith, D.4
Fitzsimmons, S.5
Chiang, Y.-T.6
Gatlin, M.7
-
68
-
-
0032418657
-
Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker
-
DOI 10.1016/S0149-2918(98)80107-0
-
Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 20(6): 1106-1114, 1998. (Pubitemid 29058413)
-
(1998)
Clinical Therapeutics
, vol.20
, Issue.6
, pp. 1106-1114
-
-
Pool, J.1
Oparil, S.2
Hedner, T.3
Glazer, R.4
Oddou-Stock, P.5
Hester, A.6
-
69
-
-
0041331792
-
Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects
-
DOI 10.1161/01.HYP.0000084855.32823.DA
-
Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42: 283-290, 2003. (Pubitemid 37093474)
-
(2003)
Hypertension
, vol.42
, Issue.3
, pp. 283-290
-
-
Hermida, R.C.1
Calvo, C.2
Ayala, D.E.3
Dominguez, M.J.4
Covelo, M.5
Fernandez, J.R.6
Mojon, A.7
Lopez, J.E.8
-
70
-
-
2342465497
-
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both
-
DOI 10.1016/S0149-2918(04)90049-5
-
Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 26(4): 460-472, 2004. (Pubitemid 38586448)
-
(2004)
Clinical Therapeutics
, vol.26
, Issue.4
, pp. 460-472
-
-
Verdecchia, P.1
Angeli, F.2
-
71
-
-
0034827191
-
Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects
-
DOI 10.1054/jcaf.2001.26242
-
Latif F, Tandon S, Obeleniene R, Hankins SR, Berlowits MS, Ennezat PV, Le Jemtel TH. Angiotensin II Type 1 receptor blockade with 80 and 160 mg Valsartan in healthy, normotensive subjects. J Card Fail 7(3): 265-268, 2001. (Pubitemid 32867967)
-
(2001)
Journal of Cardiac Failure
, vol.7
, Issue.3
, pp. 265-268
-
-
Latif, F.1
Tandon, S.2
Obeleniene, R.3
Hankins, S.R.4
Berlowitz, M.S.5
Ennezat, P.V.6
Le, J.T.H.7
-
72
-
-
0033950686
-
Newly emerging pharmacologic differences in angiotensin II receptor blockers
-
Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 13: 18-24, 2000.
-
(2000)
Am J Hypertens
, vol.13
, pp. 18-24
-
-
Oparil, S.1
-
73
-
-
2142643146
-
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
-
DOI 10.1097/00004872-200404000-00028
-
Calvo C, Hermida RC, Ayala DE, Luis M, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 22: 837-846, 2004. (Pubitemid 38543577)
-
(2004)
Journal of Hypertension
, vol.22
, Issue.4
, pp. 837-846
-
-
Calvo, C.1
Hermida, R.C.2
Ayala, D.E.3
Ruilope, L.M.4
-
74
-
-
0036384291
-
Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension
-
Wellington K, Faulds DM. Valsartan/ hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 62(13): 1983-2005, 2002.
-
(1983)
Drugs
, vol.62
, Issue.13
, pp. 2002
-
-
Wellington, K.1
Faulds, D.M.2
-
75
-
-
34447253750
-
Effects of Valsartan Alone Versus Valsartan/Simvastatin Combination on Ambulatory Blood Pressure, C-Reactive Protein, Lipoproteins, and Monocyte Chemoattractant Protein-1 in Patients with Hyperlipidemia and Hypertension
-
DOI 10.1016/j.amjcard.2007.02.085, PII S0002914907007102
-
Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 100: 222-226, 2007. (Pubitemid 47041985)
-
(2007)
American Journal of Cardiology
, vol.100
, Issue.2
, pp. 222-226
-
-
Rajagopalan, S.1
Zannad, F.2
Radauceanu, A.3
Glazer, R.4
Jia, Y.5
Prescott, M.F.6
Kariisa, M.7
Pitt, B.8
-
76
-
-
62649146826
-
Attenuation of inflammation and expansive remodeling by valsartan alone or in combination with simvastatin in high-risk coronary atherosclerotic plaques
-
Chatzizisis YS, Jonas M, Beigel R, Coskun AU, Baker AB, Stone BV, Maynard C, Gerrity RG, Daley W, Edelman ER, Feldman CL, Stone PH. Attenuation of inflammation and expansive remodeling by valsartan alone or in combination with simvastatin in high-risk coronary atherosclerotic plaques. Atherosclerosis 203: 387-394, 2009.
-
(2009)
Atherosclerosis
, vol.203
, pp. 387-394
-
-
Chatzizisis, Y.S.1
Jonas, M.2
Beigel, R.3
Coskun, A.U.4
Baker, A.B.5
Stone, B.V.6
Maynard, C.7
Gerrity, R.G.8
Daley, W.9
Edelman, E.R.10
Feldman, C.L.11
Stone, P.H.12
-
77
-
-
34447521458
-
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
-
DOI 10.1016/S0140-6736(07)61124-6, PII S0140673607611246
-
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229, 2007. (Pubitemid 47069535)
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 221-229
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Fang, H.4
Zhang, J.5
Satlin, A.6
-
78
-
-
34247471686
-
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension
-
DOI 10.1016/j.clinthera.2007.02.003, PII S0149291807000446
-
Poldermans D, Glazer R, Karagiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 29(2): 279-289, 2007. (Pubitemid 46661857)
-
(2007)
Clinical Therapeutics
, vol.29
, Issue.2
, pp. 279-289
-
-
Poldermans, D.1
Glazes, R.2
Kargiannis, S.3
Wernsing, M.4
Kaczor, J.5
Chiang, Y.T.6
Yen, J.7
Gamboa, R.8
Fomina, I.9
-
79
-
-
38949199468
-
Amlodipine/valsartan: Fixed-dose combination in hypertension
-
DOI 10.2165/00003495-200868030-00008
-
Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 68(3): 373-381, 2008. (Pubitemid 351225813)
-
(2008)
Drugs
, vol.68
, Issue.3
, pp. 373-381
-
-
Plosker, G.L.1
Robinson, D.M.2
-
80
-
-
0347405331
-
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension
-
Ke YS, Tao YY, Yang H, Yu GH. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension. Acta Pharmacol Sin 24(4): 337-341, 2003. (Pubitemid 36402199)
-
(2003)
Acta Pharmacologica Sinica
, vol.24
, Issue.4
, pp. 337-341
-
-
Ke, Y.-S.1
Tao, Y.-Y.2
Yang, H.3
Yu, G.-H.4
-
81
-
-
24344498223
-
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial
-
DOI 10.1016/j.clinthera.2005.07.010, PII S0149291805001335
-
Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 27(7): 1013-1021, 2005. (Pubitemid 41262459)
-
(2005)
Clinical Therapeutics
, vol.27
, Issue.7
, pp. 1013-1021
-
-
Lacourciere, Y.1
Poirier, L.2
Hebert, D.3
Assouline, L.4
Stolt, P.5
Rehel, B.6
Khder, Y.7
-
82
-
-
0035696052
-
Comparison of valsartan with candesartan on their possible protection from atherosclerosis
-
Mueck AO, Heuberger H, Seeger H, Wallwiener D. Comparison of valsartan with candesartan on their possible protection from atherosclerosis. J Clin Basic Cardiol 4(4): 297-299, 2001. (Pubitemid 34073363)
-
(2001)
Journal of Clinical and Basic Cardiology
, vol.4
, Issue.4
, pp. 297-299
-
-
Mueck, A.O.1
Seeger, H.2
Heuberger, W.3
Wallwiener, D.4
-
83
-
-
0034878670
-
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial
-
DOI 10.1016/S0149-2918(01)80099-0
-
Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 23(8): 1166-1179, 2001. (Pubitemid 32804112)
-
(2001)
Clinical Therapeutics
, vol.23
, Issue.8
, pp. 1166-1179
-
-
Elliott, W.J.1
Calhoun, D.A.2
DeLucca, P.T.3
Gazdick, L.P.4
Kerns, D.E.5
Zeldin, R.K.6
-
84
-
-
0032916358
-
Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring
-
DOI 10.1016/S0011-393X(00)88515-X
-
Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Pesce RM, Vanasia A. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr Ther Res 60(4): 195-206, 1999. (Pubitemid 29186441)
-
(1999)
Current Therapeutic Research - Clinical and Experimental
, vol.60
, Issue.4
, pp. 195-206
-
-
Fogari, R.1
Zoppi, A.2
Mugellini, A.3
Preti, P.4
Banderali, A.5
Pesce, R.M.6
Vanasia, A.7
-
85
-
-
0033919444
-
Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan
-
Shetty SS, Delgrande D. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharm Exp Ther 294(1): 179-186, 2000. (Pubitemid 30434685)
-
(2000)
Journal of Pharmacology and Experimental Therapeutics
, vol.294
, Issue.1
, pp. 179-186
-
-
Shetty, S.S.1
Delgrande, D.2
-
86
-
-
0033749162
-
Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: A randomized, open-label, crossover study
-
Malacco E, Piazza S, Meroni R, Milanesi A. Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study. Curr Ther Res 61(11): 789-797, 2000.
-
(2000)
Curr Ther Res
, vol.61
, Issue.11
, pp. 789-797
-
-
Malacco, E.1
Piazza, S.2
Meroni, R.3
Milanesi, A.4
-
87
-
-
0036157640
-
Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring
-
DOI 10.1016/S0011-393X(02)80002-9
-
Fogari R, Mugellini A, Zoppi A, Derosa G, Rinaldi A, Fogari E, Vanasia A, Preti P. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res 63(1): 1-14, 2002. (Pubitemid 34112219)
-
(2002)
Current Therapeutic Research - Clinical and Experimental
, vol.63
, Issue.1
, pp. 1-14
-
-
Fogari, R.1
Mugellini, A.2
Zoppi, A.3
Derosa, G.4
Rinaldi, A.5
Fogari, E.6
Vanasia, A.7
Preti, P.8
-
88
-
-
0742289119
-
Angiotensin II receptor antagonist in pregnancy
-
Morville P. Angiotensin II receptor antagonist in pregnancy. J Perinatol 24: 56-57, 2004.
-
(2004)
J Perinatol
, vol.24
, pp. 56-57
-
-
Morville, P.1
-
89
-
-
59449102286
-
Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals
-
Brambilla G, Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res 681: 209-229, 2009.
-
(2009)
Mutat Res
, vol.681
, pp. 209-229
-
-
Brambilla, G.1
Martelli, A.2
-
90
-
-
0036872988
-
Pharmacokinetics of multiple doses of valsartan in patients with heart failure
-
DOI 10.1097/00005344-200211000-00018
-
Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 40: 801-807, 2002. (Pubitemid 36109298)
-
(2002)
Journal of Cardiovascular Pharmacology
, vol.40
, Issue.5
, pp. 801-807
-
-
Prasad, P.P.1
Yeh, C.-M.2
Gurrieri, P.3
Glazer, R.4
McLeod, J.5
-
91
-
-
58849159114
-
Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension
-
Blumer J, Batisky DL, Wells T, Shi V, Yohay SS, Sunkara G. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol 49: 235-241, 2009.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 235-241
-
-
Blumer, J.1
Batisky, D.L.2
Wells, T.3
Shi, V.4
Yohay, S.S.5
Sunkara, G.6
-
92
-
-
0034088314
-
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
-
Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(1): 73-86, 2000.
-
(2000)
J Hum Hypertens
, vol.14
, Issue.1
, pp. 73-86
-
-
Israili, Z.H.1
-
93
-
-
55549110758
-
Adverse drug reactions in patients with cardiovascular disease
-
Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol 33: 703-768, 2008.
-
(2008)
Curr Probl Cardiol
, vol.33
, pp. 703-768
-
-
Faulx, M.D.1
Francis, G.S.2
-
94
-
-
12644304886
-
Pharmacokinetics of valsartan in patients with liver disease
-
DOI 10.1016/S0009-9236(97)90029-1
-
Brookman LJ, Rolan PE, Benjamin IS, Palmer KR , Wyld JP, Lloyd P, Waldmeier GFF, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 62: 272-278, 1997. (Pubitemid 27417792)
-
(1997)
Clinical Pharmacology and Therapeutics
, vol.62
, Issue.3
, pp. 272-278
-
-
Brookman, L.J.1
Rolan, P.E.2
Benjamin, I.S.3
Palmer, K.R.4
Wyld, P.J.5
Lloyd, P.6
Flesch, G.7
Waldmeier, F.8
Sioufi, A.9
Mullins, F.10
-
95
-
-
67349226863
-
Chronotherapeutic drug delivery for early morning surge in blood pressure: A programmable delivery system
-
Nayak UY, Shavi GV, Nayak Y, Averinen RK, Mutalik S, Reddy SM, Gupta PD, Udupa N. Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system. J Control Release 136(2): 125-131, 2009.
-
(2009)
J Control Release
, vol.136
, Issue.2
, pp. 125-131
-
-
Nayak, U.Y.1
Shavi, G.V.2
Nayak, Y.3
Averinen, R.K.4
Mutalik, S.5
Reddy, S.M.6
Gupta, P.D.7
Udupa, N.8
|